Amphastar Pharmaceuticals
AMPH
138 hedge funds and large institutions have $412M invested in Amphastar Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 49 increasing their positions, 49 reducing their positions, and 20 closing their positions.
25% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 20
2% more funds holding
Funds holding: 135 → 138 (+3)
0.33% more ownership
Funds ownership: 48.23% → 48.56% (+0.33%)
0% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 49
2% less capital invested
Capital invested by funds: $421M → $412M (-$9.16M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$15.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.63M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$6.3M |
| 4 |
Goldman Sachs
New York
|
+$2.4M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$1.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.8M |
| 2 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$6.46M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$2.72M |
| 4 |
Fisher Asset Management
Camas,
Washington
|
-$1.91M |
| 5 |
MC
Menta Capital
San Francisco,
California
|
-$1.59M |
AMPH Hedge Fund Activity: Q4 2016 in Review
138 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q4 2016, worth a combined $412M — down 2.2% from $421M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new AMPH positions and 20 closed out — a net gain of 5 holders — while 49 added to existing stakes and 49 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $15.9M. The largest seller was Fidelity Investments, cutting an estimated $13.8M.
- 138 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q4 2016, up from 135 in Q3 2016.
- Funds reported $412M of Amphastar Pharmaceuticals stock for Q4 2016, down 2.2% quarter-over-quarter.
- 25 funds opened new Amphastar Pharmaceuticals positions in Q4 2016 and 20 closed out, a net change of +5 holders.
- The largest Amphastar Pharmaceuticals buyer in Q4 2016 was BlackRock Fund Advisors, an estimated $15.9M added.
- The largest Amphastar Pharmaceuticals seller in Q4 2016 was Fidelity Investments, an estimated $13.8M sold.
Based on aggregated 13F filings for Q4 2016.